Artificial intelligence has shaken up nearly every industry, but nowhere is the impact more profound than in healthcare. At the center of this transformation is Tempus AI, a company using machine learning, genomics, and vast clinical datasets to personalize medical treatment. Since going public in mid-2024, Tempus AI stock has captured the attention of Wall Street, retail investors, and anyone keeping an eye on the future of AI-driven healthcare.
This deep dive covers every angle of Tempus stock—from its IPO details to its current share price, analyst forecasts, financial performance, and whether it’s a buy, hold, or sell. If you want a clear, comprehensive, and easy-to-read guide to Tempus AI as an investment, this is it.
What is Tempus AI?
Tempus AI, founded in 2015 by Eric Lefkofsky, was born out of a mission to make healthcare smarter through data. Lefkofsky, also known as the co-founder of Groupon, started the company after witnessing firsthand the gaps in cancer care. His vision was simple: harness massive amounts of clinical and molecular data and apply AI-driven analytics to improve patient outcomes.
Key facts about Tempus AI:
- Headquarters: Chicago, Illinois
- Employees: Over 2,000 as of 2024
- Focus areas: Oncology, cardiology, psychiatry, radiology, and genomics
- Core mission: Use AI-powered insights to help doctors make better, faster, and more personalized treatment decisions.
Tempus has become a leader in precision medicine, positioning itself at the intersection of two megatrends: the healthcare revolution and the AI boom.
AI IPO Overview
Tempus went public on June 14, 2024, in one of the most anticipated healthcare AI IPOs of the year. The stock trades on the NASDAQ under the ticker symbol TEM.
Here are the IPO highlights:
| Metric | Detail |
|---|---|
| IPO Price | $37 per share |
| Shares Offered | 11.1 million |
| Capital Raised | $410.7 million |
| Valuation at IPO | ~$6.1 billion |
| Opening Day Price | $40 per share |
| First-Day High | $43.64 per share |
The stock closed its debut session up nearly 9%, marking a successful entry into the public markets. For context, many tech and biotech IPOs in recent years have struggled to hold their initial pricing. Tempus not only held but rallied—a sign of strong demand.
Tempus AI Stock Price Today and Historical Performance
Since its IPO, Tempus AI stock price has been on a rollercoaster ride, typical of high-growth AI companies.
- Current Trading Range (2025): $80–82 per share
- 52-Week Low: $31.36
- 52-Week High: $91.45
- Performance Since IPO: More than doubled from $37 to over $80
This kind of volatility is expected in early-stage, high-growth stocks. For investors, it underscores the importance of timing and long-term conviction.
Tempus AI Financials and Valuation
Tempus AI is still in growth mode, which means profitability isn’t the priority yet. Instead, the focus is on scaling operations, expanding its dataset, and deepening partnerships with healthcare providers and biopharma companies.
Here’s a snapshot of Tempus’s financials:
| Financial Metric | Detail |
|---|---|
| Market Cap (2025) | ~$13 billion |
| Revenue Growth | Double-digit annual increases |
| Price-to-Sales Ratio | ~14x (growth stock territory) |
| Earnings per Share (EPS) | –$1.18 (loss-making) |
| Profitability | Not yet profitable |
The company’s valuation multiples are steep compared to traditional healthcare firms, but this is typical for AI-driven startups with disruptive potential. Investors are betting on future growth rather than present earnings.
Tempus AI Stock Forecast and Predictions
Analysts covering Tempus generally have a bullish outlook, citing its position at the cutting edge of healthcare AI.
Recent analyst price targets:
- J.P. Morgan: $42 (Over weight)
- Bank of America: $41 (Buy)
- Stifel: $45 (Buy)
While these targets reflect prices shortly after the IPO, the stock has since moved significantly higher. Analysts now see long-term upside driven by:
- Expansion into international markets (e.g., Japan joint ventures).
- Growing adoption of Tempus’s AI-powered diagnostics by oncologists and hospitals.
- Massive demand for genomics-driven precision medicine.
That said, risks like ongoing losses, regulatory challenges, and competition could temper the forecast.
Tempus AI vs Competitor Stocks
Tempus isn’t the only company operating in healthcare AI. Here’s how it stacks up against a few competitors:
| Company | Focus | Market Cap | Differentiator |
|---|---|---|---|
| Tempus AI (TEM) | AI + genomics + oncology | ~$13B | Largest clinical-molecular dataset |
| Illumina (ILMN) | Genomics/sequencing | ~$20B | Sequencing hardware dominance |
| Guardant Health (GH) | Liquid biopsies | ~$3B | Blood-based cancer detection |
| Palantir (PLTR) | Data analytics (broad) | ~$40B | Cross-industry government contracts |
Tempus’s advantage lies in integration—bringing clinical data, molecular testing, and AI analytics under one roof. This gives it a unique moat compared to point-solution competitors.
Investment Opportunity: Buy, Hold, or Sell Tempus AI Stock?
Whether Tempus AI stock is a buy depends on your investment style.
Bullish Case (Buy/Hold)
- Massive growth potential in precision medicine.
- Strategic partnerships (including a joint venture in Japan).
- Doubling stock price since IPO shows strong investor confidence.
- Unique data-driven moat that competitors can’t easily replicate.
Bearish Case (Sell/Avoid)
- Still unprofitable, with negative earnings.
- High valuation leaves little margin for error.
- Litigation risks (e.g., patent disputes with Guardant Health).
- Volatility may not suit risk-averse investors.
For growth investors with a long-term horizon, Tempus represents a high-upside opportunity in the booming AI + healthcare sector. For conservative investors, the risks may outweigh the rewards.
Tempus AI and the Future of AI in Healthcare
The bigger story here isn’t just the stock price—it’s the future of medicine. Tempus is helping usher in an era where AI and big data guide nearly every aspect of healthcare.
Potential impacts:
- Oncology: AI models predict the best personalized cancer treatment options.
- Genomics: Falling sequencing costs make population-level genetic analysis feasible.
- Clinical Trials: Tempus accelerates drug discovery by connecting pharma with real-world data.
- Global Expansion: Partnerships in Asia and Europe could make AI diagnostics widely accessible.
If this vision plays out, Tempus isn’t just another stock—it’s a transformative force in healthcare.
How to Buy Tempus AI Stock
For those looking to invest, the process is straightforward:
- Open an account with a brokerage (Fidelity, Robinhood, Charles Schwab, etc.).
- Search for the ticker TEM.
- Decide how much to invest, considering volatility.
- Place a market or limit order.
- Track earnings reports and market news regularly.
Latest Tempus AI Stock News
Recent developments that matter to investors:
- SoftBank Joint Venture in Japan: Aims to bring AI-powered treatment recommendations to Asian markets.
- Revenue Expansion: Strong adoption of AI-powered oncology and clinical tools.
- Investor Buzz: Wall Street firms highlight Tempus as one of the most promising AI healthcare companies.
FAQs About Tempus AI Stock
What is the Tempus AI stock ticker?
The ticker symbol is TEM, listed on the NASDAQ.
When did Tempus AI go public?
Tempus launched its IPO on June 14, 2024.
What is Tempus AI’s current market cap?
Around $13 billion as of 2025.
Is Tempus AI profitable?
No, Tempus is still loss-making but focused on scaling revenue growth.
Who are Tempus’s biggest competitors?
Illumina, Guardant Health, and Palantir are major players in genomics and AI-driven analytics.
Is Tempus AI stock a buy?
For aggressive growth investors, it’s a potential buy. For conservative investors, risks may be too high.
Conclusion
Tempus AI stock represents more than just a ticker symbol. It’s a window into the future of AI-powered healthcare, where precision medicine could become the standard of care. Since its IPO, Tempus has more than doubled in value, signaling strong investor confidence.
Yet, as with any high-growth AI stock, the ride will be volatile. Investors must weigh the enormous upside of Tempus’s mission against the risks of unprofitability, litigation, and valuation.
For those with patience and a belief in the fusion of AI and medicine, Tempus AI could be one of the defining stocks of the decade.
